Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature
Objective The purpose of this study was to evaluate the role of anti-vascular endothelial growth factor (anti-VEGF) treatment on the functional and structural parameters of chronic central serous retinopathy (CSR).Methods PubMed was used to systematically review literature published from 1 January 2...
Main Authors: | Monique Munro, Mathew Palakkamanil, Abhishek Sethi, Feisal Adatia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-12-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/8/1/e001310.full |
Similar Items
-
Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
by: Irini Chatziralli, et al.
Published: (2021-07-01) -
Photocoagulation in central serous retinopathy
by: Patnaik Bijayananda, et al.
Published: (1974-01-01) -
Off-label intravitreal Brolucizumab in the management of central serous chorioretinopathy
by: Pradeep Kumar Panigrahi, et al.
Published: (2024-01-01) -
Evaluation of the effect of intravitreal antivascular endothelial growth factor versus medical treatment in acute central serous chorioretinopathy
by: Moataz A Sallam
Published: (2022-01-01) -
Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy
by: K Sandeep, et al.
Published: (2023-01-01)